Autoimmunity and neurological disease: Antibody modulation of synaptic transmission

Annual Review of Neuroscience

Volumn 22, Issue , 1999, Pages 175-195

  Whitney, K D ^a   McNamara, J O ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Autoantibodies; Neurotransmission; Receptor; Voltage dependent calcium channel; Voltage dependent potassium channel

Indexed keywords

ALPHA BUNGAROTOXIN; AUTOANTIBODY; CALCIUM CHANNEL; CHOLINERGIC RECEPTOR; GLUTAMATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; IODINE 125; POTASSIUM CHANNEL; RECEPTOR ANTIBODY;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC TRANSMISSION; EATON LAMBERT SYNDROME; EPILEPSY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOKYMIA; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RASMUSSEN SYNDROME; REVIEW; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIBODIES; AUTOIMMUNITY; HUMANS; NERVOUS SYSTEM DISEASES; SYNAPTIC TRANSMISSION;

EID: 0032964881     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.22.1.175     Document Type: Review

References (98)

1. Adcock JE, Oxbury JM, Beeson D, Middleton JA, Matkovic Z, et al. 1997. Comparison of treatment of Rasmussen's encephalitis with plasmapheresis versus hemispherectomy. Epilepsia 38 (Suppl. 8):189
2. Aiba A, Kano M, Chen C, Stanton ME, Fox GD, et al. 1994. Deficient cerebellar longterm depression and impaired motor learning in mGluR1 mutant mice. Cell 79:377-88
3. Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. 1996. Plasmapheresis in Rasmussen's encephalitis. Neurology 46:242-46
4. Atkins MR, Terrell W, Hulette CM. 1995. Rasmussen's syndrome: a study of potential viral etiology. Clin. Neuropathol. 14:7-12
5. Ben-Ari Y, Lagowska J, Tremblay E, Le Gal La Salle G. 1979. A new model of focal status epilepticus: intra-amygdaloid application of kainic acid elicits repetitive secondarily generalized convulsive seizures. Brain Res. 163:176-79
6. Borda ES, Sterin-Borda L. 1996. Antiadrenergic and muscarinic receptor antibodies in Chagas' cardiomyopathy. Int. J. Cardiol. 54:149-56
7. Broadwell RD, Sofroniew MV. 1993. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp. Neurol. 120:245-63
8. Brocke S, Piercy C, Steinman L. 1996. Super-antigens in demyelinating disease. Springer Semin. Immunopathol. 18:51-6
9. Buchner RR, Vogen SM, Fischer W, Thoman ML, Sanderson SD, Morgan EL. 1997. Anti-human kappa opioid receptor antibodies: characterization of site-directed neutralizing antibodies specific for a peptide kappa R(3352) derived from the predicted amino terminal region of the human kappa receptor. J. Immunol. 158:1670-80
10. Bufler J, Kahlert S, Tzartos S, Toyka KV, Maelicke A, Franke C. 1996. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J. Physiol. 492:107-14
11. Carlson NG, Gahring LC, Twyman RE, Rogers SW. 1997. Identification of amino acids in the glutamate receptor, GluR3, important for antibody-binding and receptor-specific activation. J. Biol. Chem. 272:11295-301
12. Choi DW. 1992. Excitotoxic cell death. J. Neurobiol. 23:1261-76
13. Conquet F, Bashir ZI, Davies CH, Daniel H, Ferraguti F, et al. 1994. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature 372:237-43
14. Cossio PM, Laguens RP, Kreutzer E, Diez C, Segal A, Arana RM. 1977. Chagasic cardiopathy. Am. J. Pathol. 86:533-44
15. David C, McPherson PS, Mundigl O, DeCamilli P. 1996. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc. Natl. Acad Sci. USA 93:331-35
16. Drachman DB. 1994. Myasthenia gravis. N. Engl. J. Med. 330:1797-810
17. Engel AG, Arahata K. 1987. The membrane attack complex of complement at the end-plate in myasthenia gravis. Ann. NY Acad. Sci. 505:326-31
18. Engel AG, Lambert EH, Howard FM. 1977. Immune complexes (IgG and C3) at the motor endplate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52:267-80
19. Farrell MA, DeRosa MJ, Curran JG, Secor DL, Cornford ME, et al. 1992. Neuropathologic findings in cortical resections (including hemispherectomies) performed for the treatment of intractable childhood epilepsy. Acta Neuropathol. 83:246-59
20. Farrell MA, Droogan O, Secor DL, Poukens V, Quinn B, Vinters HV. 1995. Chronic encephalitis associated with epilepsy: immunohistochemical and ultrastructural studies. Acta Neuropathol. 89:313-21
21. Ferrari I, Levin MJ, Wallukat G, Elies R, Lebesgue D, et al. 1995. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J. Exp. Med. 182:59-65
22. Friedman A, Kaufer D, Shemer J, Hendler I, Soreq H, Tur-Kaspa I. 1996. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate gene response. Nat. Med. 2:1382-85
23. Fu ML. 1996. Anti-M2 muscarinic receptor autoantibodies and idiopathic dilated cardiomyopathy. Int. J. Cardiol. 54:127-35
24. Ganguli R, Brar JS, Chengappa KN, Yang ZW, Nimgaonkar VL, Rabin BS. 1993. Autoimmunity in schizophrenia: a review of recent findings. Ann. Med. 25:489-96
25. García KD, Beam KG. 1996. Reduction of calcium currents by Lambert-Eaton syndrome sera: motoneurons are preferentially affected, and L-type currents are spared. J. Neurosci. 16:4903-13
26. 2+ currents in murine dorsal root ganglion neurons. Proc. Natl. Acad. Sci. USA 93:9264-69
27. Garzon J, Sanchez-Blazquez P. 1995. In vivo injection of antibodies directed against the cloned mu opioid receptor blocked supraspinal analgesia induced by mu-agonists in mice. Life Sci. 56:L237-42
28. Hall ZW, Pizzighella S, Gu Y, Vicini S, Schuetze SM. 1987. Functional inhibition of acetylcholine receptors by antibodies in myasthenic sera. Ann. NY Acad. Sci. 505:272-85
29. + channels are implicated in neuromyotonia. Ann. Neurol. 41:238-46
30. He X-P, Patel M, Whitney KD, Janumpalli S, Tenner A, McNamara JO. 1997. Glutamate receptor GluR3 antibodies and death of cortical cells. Neuron 20:153-63
31. Hoedemaekers ACWE, van Breda Vriesman PJC, De Baets MH. 1997. Myasthenia gravis as a prototype autoimmune receptor disease. Immunol. Res. 16:341-47
32. Hollman M, Heinemann S. 1994. Cloned glutamate receptors. Annu. Rev Neurosci. 17:31-108
33. Hood L, Kumar V, Osman G, Beall SS, Gomez C, et al. 1989. Autoimmune disease and T-cell immunologic recognition. Cold Spring Harbor Symp. Quant. Biol. 54:859-74
34. Husby G, Van den Rijn I, Zabriske JB, Abdin ZH, Williams RC Jr. 1976. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J. Exp. Med. 144:1094-110
35. Isaacs H. 1961. A syndrome of continuous muscle-fibre activity. J. Neurol. Neurosurg. Psychiatry 24:319-25
36. Jan LY, Jan YN. 1997. Cloned potassium channels from eukaryotes and prokaryotes. Annu. Rev. Neurosci. 20:91-123
37. Jay V, Becker LE, Ostubo H, Cortez M, Hwang P, et al. 1995. Chronic encephalitis and epilepsy (Rasmussen's encephalitis): detection of cytomegalovirus and herpes simplex virus 1 by the polymerase chain reaction and in situ hybridization. Neurology 45:108-17
38. Karlin A, Akabas MH. 1995. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 15:1231-44
39. Kim YI. 1986. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 9:523-30
40. Kim YI, Neher E. 1988. IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels. Science 239:405-8
41. Lambert EH, Eaton LM, Rooke ED. 1956. Defect of neuromuscular conduction associated with malignant neoplasms. Am. J. Physiol. 187:612-13
42. Lambert EH, Elmqvist D. 1971. Quantal components of end-plate potentials in the myasthenic syndrome. Ann. NY Acad. Sci. 183:183-99
43. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. 1981. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2:224-26
44. Lang B, Vincent A. 1996. Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr. Opin. Immunol. 8:865-71
45. Lang TJ, Badea TC, Wade R, Shin ML. 1997. Sublytic terminal complement attack on myotubes decreases the expression of mRNAs encoding muscle-specific proteins. J. Neurochem. 68:1581-89
46. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155-57
47. Lennon VA. 1994. Serological diagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. In Serological Diagnosis of Myasthenia Gravis and the Lambert-Eaton Myasthenic Syndrome, ed. RP Lisak, pp. 149-64. New York: Dekker
48. Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, et al. 1995. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N. Engl. J. Med. 332:1467-74
49. Lennon VA, Lambert EH. 1980. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 285:238-40
50. Lennon VA, Lambert EH, Leiby KR, Okarma TB, Talib S. 1991. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146:2245-48
51. Lennon VA, McCormick DJ, Lambert EH, Griesmann GE, Atassi MZ. 1985. Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc. Natl. Acad. Sci. USA 82:8805-9
52. Lennon VA, Seybold ME, Lindstrom JM, Cochrane C, Ulevitch R. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147:973-83
53. Limas CJ, Limas C. 1993. Immune-mediated modulation of beta-adrenoceptor function in human dilated cardiomyopathy. Clin. Immunol. Immunopathol. 68:204-7
54. Lindstrom J, Shelton D, Fujii Y. 1988. Myasthenia gravis. Adv. Immunol. 42:233-84
55. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. 1976. Antibody to acetylcholine receptor in myasthenia gravis. Neurology 26:1054-59
56. Magnusson Y, Hjalmarson A, Hoebeke J. 1996. Beta 1-adrenoceptor autoimmunity in cardiomyopathy. Int. J. Cardiol. 54:137-41
57. Matsui S, Fu MLX, Katsuda S, Hayase M, Yamaguchi N, et al. 1997. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J. Mol. Cell. Cardiol. 29:641-55
58. McRae-Deguerce A, Gottfries CG, Karlsson I, Svennerholm L, Dahlstrom A. 1986. Antibodies in the CSF of parkisonian patient recognizes neurons in rat mesencephalic regions. Acta Physiol. Scand. 126:313-15
59. Miller RJ. 1997. Calcium channels prove to be a real headache. Trends Neurosci. 20:189-92
60. Morgan BP, Gasque P. 1996. Expression of complement in the brain: role in health and disease. Immunol. Today 17:461-66
61. Newsom-Davis J, Murray NMF. 1984. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrom. Neurology 34:480-85
62. Newsom-Davis J, Wilson SG, Vincent A, Ward CD. 1979. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1:464-68
63. Nitsch C, Klatzo I. 1983. Regional patterns of blood-brain barrier breakdown during epileptiform seizures induced by various convulsive agents. J. Neurol. Sci. 59:305-22
64. Oguni H, Andermann F, Rasmussen TB. 1992. The syndrome of chronic encephalitis and epilepsy - a study based on the MNI series of 48 cases. Adv. Neurol. 57:419-33
65. Oldstone MBA. 1987. Molecular mimicry and autoimmune disease. Cell 50:819-20
66. Patrick J, Lindstrom J. 1973. Autoimmune response to acetylcholine receptor. Science 180:871-72
67. Peers C, Johnston I, Lang B, Wray D. 1993. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neurosci. Lett. 153:45-48
68. Perez-Leiros C, Sterin-Borda L, Borda ES, Goin JC, Hosey MM. 1997. Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas' disease. J. Biol. Chem. 272:12989-93
69. Phillips WD, Vladeta D, Han H, Noakes PG. 1997. Rapsyn and agrin slow the metabolic degradation of the acetylcholine receptor. Mol. Cell. Neurosci. 10:16-26
70. Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP. 1996. Soluble complement receptor 1(sCR1) protects against experimental autoimmune myasthenia gravis. J. Neurochem. 71:173-77
71. Pin J-P, Duvoisin R. 1995. Review: neurotransmitter receptors I. Neuropharmacology 34:1-26
72. Posner JB, Dalmau JO. 1997. Paraneoplastic syndromes affecting the central nervous system. Annu. Rev. Med. 48:157-66
73. Power C, Poland SD, Blume WT, Girvin JP, Rice GPA. 1990. Cytomegalovirus and Rasmussen's encephalitis. Lancet 336:1282-84
74. Rasmussen T, Olszweski J, Lloyd-Smith D. 1958. Focal seizures due to chronic localized encephalitis. Neurology 8:435-55
75. Renno T, Acha-Orbea H. 1996. Superantigens in autoimmune diseases: still more shades of gray. Immunol. Rev. 154:175-91
76. Riemersma S, Vincent A, Beeson D, Newland C, Hawke S, et al. 1996. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J. Clin. Invest. 98:2358-63
77. 2+ flux in a human small cell carcinoma line. Nature 317:73-75
78. Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, et al. 1994. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265:648-51
79. Sanders DP, Andrews PI, Howard JF Jr, Massey JM. 1997. Seronegative myasthenia gravis. Neurology 48 (Suppl. 5):S40-45
80. Schuetze SM, Vicini S, Hall ZW. 1985. Myasthenic serum selectively blocks acetylcholine receptors with long channel open times at developing rat endplates. Proc. Natl. Acad. Sci. USA 82:2533-37
81. Sciamanna MA, Griesmann GE, Williams CL, Lennon VA. 1997. Nicotinic acetylcholine receptors of muscle and neuronal (alpha(7)) types coexpressed in a small cell lung carcinoma. J. Neurochem. 69:2302-11
82. Scolding NJ, Morgan BP, Houston WAJ, Linington C, Campbell AK, Compston DAS. 1989. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339:620-22
83. Shigemoto R, Abe T, Nomura S, Nakanishsi S, Hirano T. 1994. Antibodies inactivating mGluR1 metabotropic glutamate receptor block long-term depression in cultured purkinje cells. Neuron 12:1245-55
84. + channels of peripheral nerves. Ann. Neurol. 38:714-22
85. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. 1991. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 338:75-77
86. Staddon JM, Rubin LL. 1996. Cell adhesion, cell junctions, and the blood-brain barrier. Curr. Opin. Neurobiol. 6:622-27
87. Steinman L. 1996. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302
88. Stern-Bach Y, Bettler B, Harley M, Sheppard PO, O'Hara PJ, Heinemann SF 1994. Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins. Neuron 13:1345-57
89. Sudhof TC. 1995. The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature 375:645-53
90. Takamori M, Hamada T, Komai K, Takahashi M, Yoshida A. 1994. Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Ann. Neurol. 35:74-80
91. Takamori M, Iwasa K, Kiyonobu K. 1997. Antibodies to synthetic peptides of the a1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 48:1261-65
92. Toyka KV, Brachman DB, Pestronk A, Kao I. 1975. Myasthenia gravis: passive transfer from man to mouse. Science 190:397-99
93. Twyman RE, Gahring LC, Spiess J, Rogers SW. 1995. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 14:755-62
94. Vernet-der Garabedian B, Lacokova M, Eymard B, Morel E, Faltin M, et al. 1994. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor. J. Clin. Invest. 94:555-59
95. Vincent A, Lang B, Newsom-Davis J. 1989. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 12:496-502
96. Waterman SA, Lang B, Newsom-Davis J. 1997. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann. Neurol. 42:147-56
97. Wu L-G, Saggau P. 1997. Presynaptic inhibition of elicited neurotransmitter release. Trends Neurosci. 20:204-12
98. Wucherpfennig KW, Strominger JL. 1995. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705